LIBTAYO was studied in a clinical trial that compared patients with advanced NSCLC who received LIBTAYO at 350 mg every 3 weeks with those who received chemotherapy containing platinum. The study was designed to include patients if their tumor tested positive for the biomarker PD-L1 at a level greater than or equal to 50% and if they did not have abnormal EGFR, ALK, or ROS1 genes. A total of 710 patients were included in the study.
Median overall survival (OS)*
*Median overall survival (OS) is the time in a trial—expressed in months or years—when half of the patients are still living.